TY - JOUR

T1 - Production of polycaprolactone nanoparticles with hydrodynamic diameters below 100 nm

AU - Witt, Sandra

AU - Scheper, Thomas

AU - Walter, Johanna Gabriela

N1 - Funding Information: We would like to thank Dr. Gerrit Jürjens (Helmholtz Zentrum München) for H‐NMR measurements and the Institute for Physical Chemistry and Electrochemistry (Leibniz University Hannover) for access to the Nanoparticle Tracking Analysis (NTA). Furthermore, the authors thank Bilal Temel for TEM measurement and the Laboratory of Nano and Quantum Engineering (LNQE) of the Leibniz University of Hannover for the TEM instrument. This work was funded by the Lower Saxony Ministry for Science and Culture (MWK). 1

PY - 2019/10/7

Y1 - 2019/10/7

N2 - Cancer is a worldwide increasing burden and its therapy is often challenging and causes severe side effects in healthy tissue. If drugs are loaded into nanoparticles, side effects can be reduced, and efficiency can be increased via the enhanced permeability and retention effect. This effect is based on the fact that nanoparticles with sizes from 10 to 200 nm can accumulate in tumor tissue due to their leaky vasculature. In this work, we produced polycaprolactone (PCL) in the sizes 1.8, 5.4, and 13.6 kDa and were able to produce spherical shaped nanoparticles with mean diameters of 64 ± 19 nm out of the PCL5.4 and 45 ± 8 nm out of the PCL13.6 reproducibly. By encapsulation of paclitaxel the diameter of that nanoparticles did not increase, and we were able to encapsulate 73 ± 7 fmol paclitaxel per 1000 particles in the PCL5.4-nanoparticles and 35 ± 8 fmol PTX per 1000 PCL13.6-nanoparticles. Furthermore, we coupled the aptamer S15 to preformed PCL5.4-nanoparticles resulting in particles with a hydrodynamic diameter of 153 nm. This offers the opportunity to use these nanoparticles for targeted drug delivery.

AB - Cancer is a worldwide increasing burden and its therapy is often challenging and causes severe side effects in healthy tissue. If drugs are loaded into nanoparticles, side effects can be reduced, and efficiency can be increased via the enhanced permeability and retention effect. This effect is based on the fact that nanoparticles with sizes from 10 to 200 nm can accumulate in tumor tissue due to their leaky vasculature. In this work, we produced polycaprolactone (PCL) in the sizes 1.8, 5.4, and 13.6 kDa and were able to produce spherical shaped nanoparticles with mean diameters of 64 ± 19 nm out of the PCL5.4 and 45 ± 8 nm out of the PCL13.6 reproducibly. By encapsulation of paclitaxel the diameter of that nanoparticles did not increase, and we were able to encapsulate 73 ± 7 fmol paclitaxel per 1000 particles in the PCL5.4-nanoparticles and 35 ± 8 fmol PTX per 1000 PCL13.6-nanoparticles. Furthermore, we coupled the aptamer S15 to preformed PCL5.4-nanoparticles resulting in particles with a hydrodynamic diameter of 153 nm. This offers the opportunity to use these nanoparticles for targeted drug delivery.

KW - aptamer

KW - nanoparticle

KW - paclitaxel

KW - polycaprolactone

UR - http://www.scopus.com/inward/record.url?scp=85070712274&partnerID=8YFLogxK

U2 - 10.1002/elsc.201800214

DO - 10.1002/elsc.201800214

M3 - Article

AN - SCOPUS:85070712274

VL - 19

SP - 658

EP - 665

JO - Engineering in life sciences

JF - Engineering in life sciences

SN - 1618-0240

IS - 10

ER -